CEL-SCI Corporation CVM

Company Overview

CEL-SCI Corporation is a U.S.-based biotechnology company focused on the development of immunotherapy products for the treatment of cancer, infectious diseases, and inflammatory conditions. The company operates within the biotechnology and biopharmaceutical industries, with its primary emphasis on immuno-oncology. CEL-SCI’s lead product candidate is Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy designed for the treatment of newly diagnosed locally advanced primary head and neck cancer prior to surgery and radiation. The company has also developed investigational technologies related to peptide-based immunotherapy and immune system modulation.

The company’s principal revenue driver has historically been capital raising activities rather than commercial product sales, as it remains in the clinical-stage biotechnology phase without approved commercial therapies. CEL-SCI positions itself around the concept of administering immune-based therapies early in the disease treatment cycle, particularly before conventional treatments may suppress immune function. Founded in 1983 and headquartered in Vienna, Virginia, the company has evolved from a broad immunotherapy research organization into a more focused oncology development company centered on advancing Multikine through clinical development and regulatory engagement.